Orthocell has been featured in The West Australian in an article by Sean Smith titled “Orthocell cracks a new record high.”
The article highlights the Company’s outstanding recent performance on the ASX, after receiving approval to sell Remplir in Singapore.
Here’s an excerpt:
“Having raised cash at 37¢ and 60¢ a share last year from the likes of Chris Ellison, Rod Jones, the McCusker family and Chris Judd, the fast-running biotech has been among the ASX’s best performers over the past six weeks, cracking $1.50 on Friday to take its gain over the past 12 months to 263 per cent.
“The shares hit a peak of $1.52 before closing out the shortened trading week 4¢ higher on the day at $1.49, revaluing the University of Western Australia-founded group at $347m.”